MedTrace Logo

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

NCT05597241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-04-11

No results posted yet for this study

Summary

To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers

Conditions

Interventions

DRUG

apimostinel

N-methyl-D-aspartate (NMDA) receptor modulator

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Syndeio Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Ronald M Burch, MD PhD · Syndeio Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-15
Primary Completion
2023-04-04
Completion
2023-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05597241 on ClinicalTrials.gov